+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Economic, Public Health, and Humanistic Impact of a Quadrivalent Human Papillomavirus (Hpv6/11/16/18) Vaccination Program for Females Age 9-11 Years in Mexico



Economic, Public Health, and Humanistic Impact of a Quadrivalent Human Papillomavirus (Hpv6/11/16/18) Vaccination Program for Females Age 9-11 Years in Mexico



Value in Health 18(7): A871




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057685990

Download citation: RISBibTeXText

PMID: 26534664

DOI: 10.1016/j.jval.2015.09.014


Related references

Economic, Public Health, And Humanistic Impact of a Quadrivalent Human Papillomavirus (Hpv6/11/16/18) Vaccination Program For Females And Males Age 9-11 Years in Mexico. Value in Health 18(7): A821-A822, 2015

Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: public health implications for the region. Archives of Medical Research 40(6): 514-524, 2010

Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands. Journal of Infectious Diseases 216(2): 210-219, 2017

The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 26(35): 4513-4518, 2008

Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. Value in Health 11(7): 1022-1032, 2008

Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females. Vaccine 34(1): 172-178, 2016

The Health and Economic Impact of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) in Columbia: A Transmission Dynamic Model-Based Evaluation. Value in Health 16(7): A713-A714, 2013

Cost-Effectiveness of Quadrivalent Human Papilloma Virus (Hpv6/11/16/18) Vaccination In Ecuador. Value in Health 18(7): A834, 2015

Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clinical and Vaccine Immunology 22(8): 943-948, 2016

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa. Human Vaccines & Immunotherapeutics 11(6): 1323-1330, 2016

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26(1): 128-139, 2007

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. Bjog 115(8): 947-956, 2008

The Epidemiological and Economic Impact of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) in the Uk. Obstetrical & Gynecological Survey 63(10): 637-638, 2008

Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure. Gynecologic Oncology 146(2): 299-304, 2017

The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia. Bmc Infectious Diseases 13: 304, 2014